<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040935</url>
  </required_header>
  <id_info>
    <org_study_id>ML28878</org_study_id>
    <secondary_id>2013-000829-31</secondary_id>
    <nct_id>NCT02040935</nct_id>
  </id_info>
  <brief_title>A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants</brief_title>
  <acronym>HOMERUS</acronym>
  <official_title>HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This single-arm, open-label, local multicenter study will evaluate the safety and
      tolerability of trastuzumab administered subcutaneously (SC) by a single-use injection device
      (SID) in participants with human epidermal growth factor receptor 2 (HER2)-positive early
      breast cancer (EBC), following surgery and chemotherapy (neo-adjuvant or adjuvant).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 21, 2014</start_date>
  <completion_date type="Anticipated">July 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>From Baseline up to approximately 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Trough Concentrations (Ctrough) of Trastuzumab</measure>
    <time_frame>Pre-dose (within 1 day before trastuzumab administration) at Cycles 2, 3, 9, and 10, 12 or 13 (cycle length=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Survey Short Form-36 (SF-36) Score</measure>
    <time_frame>Cycles 3 and 9 (cycle length=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood and Anxiety Questionnaire (MASQ) Score</measure>
    <time_frame>Cycles 3 and 9 (cycle length=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Choosing to Return to Hospital Administration</measure>
    <time_frame>Cycle 6 (cycle length=21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>600 mg SC Q3W by SID</description>
    <arm_group_label>Trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast

          -  HER2-positive disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Hormonal therapy will be allowed as per institutional guidelines

          -  Prior use of anti-HER2 therapy will be allowed

          -  Left ventricular ejection fraction (LVEF) greater than or equal to (&gt;/=) 50 percent
             (%)

          -  No evidence of residual, locally recurrent or metastatic disease after completion of
             surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or adjuvant)

          -  Use of concurrent radiotherapy will be permitted

          -  Completion of surgery and chemotherapy (if applicable)

        Exclusion Criteria:

          -  History of other malignancy, except for participants with curatively treated carcinoma
             in situ of the cervix or basal cell carcinoma and participants with other curatively
             treated malignancies who have been disease-free for the last 5 years

          -  Participants with severe dyspnea at rest or requiring supplementary oxygen therapy

          -  Participants with other concurrent serious diseases that might interfere with planned
             treatment, including severe pulmonary conditions/illness

          -  Serious cardiac illness or medical conditions that would preclude the use of
             trastuzumab, specifically: history of documented congestive heart failure, high-risk
             uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant
             valvular disease, evidence of transmural infarction on electrocardiogram (ECG), poorly
             controlled hypertension

          -  Pregnant or lactating women

          -  Women of childbearing potential and male participants with female partners of
             childbearing potential who are unable or unwilling to use adequate contraceptive
             methods during study treatment

          -  Concurrent enrollment in another clinical trial using an investigational anti-cancer
             treatment, including hormonal therapy, biphosphonate therapy and immunotherapy, within
             28 days prior to the first dose of study treatment

          -  Known hypersensitivity to trastuzumab, murine proteins, to any excipients of
             Herceptin, including hyaluronidase, or the adhesive of the SC device, or a history of
             severe allergic or immunological reactions, e.g. difficult to control asthma

          -  Inadequate hepatic or renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum; Locatie Lichtenberg</name>
      <address>
        <city>Amersfoort</city>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia ziekenhuis, locatie langendijk</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IJsselland Ziekenhuis</name>
      <address>
        <city>Capelle Aan De Yssel</city>
        <zip>2906 ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis; Oncology</name>
      <address>
        <city>Delft</city>
        <zip>2600 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <zip>2504 LN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei; Inwendige Geneeskunde</name>
      <address>
        <city>EDE</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <zip>9728 MG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <zip>2035 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente, Hengelo</name>
      <address>
        <city>Hengelo</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen, loc. Hilversum</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis Haarlem; Oncologie</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscus Ziekenhuis</name>
      <address>
        <city>Roosendaal</city>
        <zip>4708 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland ziekenhuis locatie Geleen</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri - Medisch Centrum voor Noord-Limburg</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

